Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 5/20 | 0.48 |
| ▸ | ADH1C | P00326 | 4/20 | 0.48 |
| ▸ | ADH1B | P00325 | 2/20 | 0.48 |
| ▸ | ADH4 | P08319 | 2/20 | 0.48 |
| ▸ | ADH7 | P40394 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21114239 | 1.00 | ADH1A (0.48) | ADH1AADH1CADH1BADH4ADH7 | |
| SCHEMBL21114319 | 1.00 | ADH1A (0.48) | ADH1AADH1CADH1BADH4ADH7 | |
| SCHEMBL5935694 | 1.00 | ADH1A (0.48) | ADH1AADH1CADH1BADH4ADH7 | |
| SCHEMBL16520916 | 1.00 | ADH1A (0.48) | ADH1AADH1CADH1BADH4ADH7 | |
| SCHEMBL5796235 | 1.00 | ADH1A (0.48) | ADH1AADH1CADH1BADH4ADH7 | |
| SCHEMBL26244 | 1.00 | — | — | |
| SCHEMBL21114270 | 1.00 | ADH1A (0.48) | ADH1AADH1CADH1BADH4ADH7 | |
| SCHEMBL28560855 | 0.97 | ADH1A (0.46) | ADH1AADH1CADH1BADH4ADH7 | |
| SCHEMBL28548671 | 0.97 | ADH1A (0.46) | ADH1AADH1CADH1BADH4ADH7 | |
| SCHEMBL28564230 | 0.97 | ADH1A (0.46) | ADH1AADH1CADH1BADH4ADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109790284-B | Polyphenol compound and process for producing the same | 三菱化学株式会社 | 2021-09-21 | — | — | CN | disclosed |
| US-10851039-B2 | Polyhydric phenol compound and method of producing same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2020-12-01 | — | — | US | disclosed |
| US-10793499-B2 | — | — | 2020-10-06 | — | — | US | disclosed |
| EP-3514193-A1 | POLYVALENT PHENOL COMPOUND AND METHOD OF PRODUCING SAME | Mitsubishi Chemical Corporation (JP) | 2019-07-24 | — | — | EP | disclosed |
| US-20190210947-A1 | POLYHYDRIC PHENOL COMPOUND AND METHOD OF PRODUCING SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-07-11 | — | — | US | disclosed |
| EP-1443046-B1 | NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME, PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME | KYORIN SEIYAKU KK (JP) | 2008-12-17 | — | — | EP | disclosed |
| EP-1443046-B1 | NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME, PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME | KYORIN SEIYAKU KK (JP) | 2008-12-17 | — | — | EP | disclosed |
| US-20080194826-A1 | Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same | KYORIN PHARMACEUTICAL CO., LTD. | 2008-08-14 | — | — | US | disclosed |
| US-20080194826-A1 | Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same | KYORIN PHARMACEUTICAL CO., LTD. | 2008-08-14 | — | — | US | disclosed |
| US-20080194826-A1 | Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same | KYORIN PHARMACEUTICAL CO., LTD. | 2008-08-14 | — | — | US | disclosed |
| US-7375115-B2 | 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7375115-B2 | 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7375115-B2 | 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20050085508-A1 | Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1443046-A1 | NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME, PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME | Kyorin Pharmaceutical Co., Ltd. (JP) | 2004-08-04 | — | — | EP | disclosed |
| US-6252118-B1 | REACTING A KETONE HAVING A BETA HYDROGEN WITH AN OLEFIN CATALYZED BY A TRANSITION METAL CATALYST COMPOUND WITH THE AID OF A 2-AMINOPYRIDINE DERIVATIVE | Jun, Chul Ho (KR) | 2001-06-26 | — | — | US | disclosed |
| US-6140338-A | FOR TREATING ACUTE INFLAMMATORY DISEASES, CHRONIC INFLAMMATORY DISEASES, ACQUIRED IMMUNE DEFICIENCY SYNDROME, CANCER, ISCHEMIC REFLOW DISORDER AND/OR ARTERIOSCLEROSIS | BANYU PHARMACEUTICAL, CO., LTD. (JP) | 2000-10-31 | — | — | US | disclosed |
| EP-0916668-A1 | CHEMOKINE RECEPTOR ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210947-A1 | POLYHYDRIC PHENOL COMPOUND AND METHOD OF PRODUCING SAME | RB1, FHIT, H1-4 | ADH1A 646/4885ADH1C 467/4885ADH1B 123/4885 |
| US-20080194826-A1 | Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same | CYP4F2, CYP1A2, CYP4B1 | ADH1A 316/4885ADH1C 677/4885ADH1B 687/4885 |
| US-10851039-B2 | Polyhydric phenol compound and method of producing same | RB1, FHIT, H1-4 | ADH1A 646/4885ADH1C 467/4885ADH1B 123/4885 |
| US-20050085508-A1 | Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same | OPRM1, OPRD1, HRH4 | ADH1A 2220/4885ADH1C 2374/4885ADH1B 4092/4885 |
| US-10793499-B2 | — | RB1, H1-4, TPD52L2 | ADH1A 817/4885ADH1C 772/4885ADH1B 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.